Quince Therapeutics (QNCX) Other Non Operating Income (2018 - 2026)

Quince Therapeutics' Other Non Operating Income history runs 7 years deep, the most recent figure standing at $1.7 million for Q1 2026.

• In Q1 2026, Other Non Operating Income rose 2075.86% year-over-year to $1.7 million; the TTM figure through Mar 2026 stood at $2.3 million (up 729.67% YoY), while the FY2025 annual figure was $486000.0, up 171.89% from the prior year.
• Other Non Operating Income for Q1 2026 stood at $1.7 million, up from $660000.0 in the prior quarter.
• The five-year high for Other Non Operating Income was $1.7 million in Q1 2026, with the low at -$735000.0 in Q2 2022.
• The 5-year median for Other Non Operating Income is -$58000.0 (2025), against an average of $24117.6.
• The sharpest annual moves came in 2022 and 2026: Other Non Operating Income sank 461.07% in 2022, then soared 2075.86% in 2026.
• Quince Therapeutics' Other Non Operating Income stood at $249000.0 in 2022, then surged by 61.45% to $402000.0 in 2023, then tumbled by 228.86% to -$518000.0 in 2024, then surged by 227.41% to $660000.0 in 2025, then surged by 160.45% to $1.7 million in 2026.
• Business Quant data shows QNCX's Other Non Operating Income at $1.7 million in Q1 2026, $660000.0 in Q4 2025, and -$58000.0 in Q3 2025.